Concepts (148)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anti-Bacterial Agents | 14 | 2024 | 735 | 1.440 |
Why?
|
| Klebsiella Infections | 2 | 2021 | 21 | 1.340 |
Why?
|
| Klebsiella pneumoniae | 2 | 2021 | 26 | 1.330 |
Why?
|
| Bacteremia | 3 | 2021 | 91 | 1.330 |
Why?
|
| Hospitalization | 5 | 2024 | 1292 | 1.290 |
Why?
|
| beta-Lactamases | 5 | 2021 | 13 | 1.230 |
Why?
|
| Internal Medicine | 4 | 2024 | 154 | 1.120 |
Why?
|
| Escherichia coli Infections | 2 | 2018 | 86 | 1.110 |
Why?
|
| Escherichia coli | 3 | 2018 | 695 | 0.980 |
Why?
|
| Emergency Service, Hospital | 3 | 2021 | 1022 | 0.940 |
Why?
|
| Chloramphenicol | 1 | 2024 | 5 | 0.920 |
Why?
|
| Risk Adjustment | 2 | 2024 | 93 | 0.900 |
Why?
|
| Israel | 7 | 2024 | 17 | 0.830 |
Why?
|
| Crowding | 1 | 2021 | 34 | 0.740 |
Why?
|
| Colistin | 1 | 2021 | 7 | 0.730 |
Why?
|
| Febrile Neutropenia | 1 | 2018 | 4 | 0.630 |
Why?
|
| Inpatients | 1 | 2021 | 292 | 0.580 |
Why?
|
| Cattle Diseases | 1 | 2017 | 9 | 0.550 |
Why?
|
| Career Choice | 1 | 2018 | 120 | 0.540 |
Why?
|
| Pandemics | 2 | 2021 | 617 | 0.520 |
Why?
|
| Diabetic Foot | 1 | 2016 | 11 | 0.510 |
Why?
|
| Carbapenems | 3 | 2020 | 6 | 0.490 |
Why?
|
| Staphylococcal Infections | 3 | 2016 | 122 | 0.450 |
Why?
|
| Daptomycin | 3 | 2009 | 9 | 0.440 |
Why?
|
| Tertiary Care Centers | 2 | 2024 | 100 | 0.440 |
Why?
|
| Length of Stay | 3 | 2024 | 776 | 0.430 |
Why?
|
| Enterobacteriaceae Infections | 3 | 2020 | 10 | 0.430 |
Why?
|
| Enterobacteriaceae | 3 | 2020 | 14 | 0.420 |
Why?
|
| Humans | 29 | 2024 | 59389 | 0.370 |
Why?
|
| Staphylococcus aureus | 3 | 2016 | 169 | 0.360 |
Why?
|
| Retrospective Studies | 9 | 2024 | 6071 | 0.360 |
Why?
|
| Internship and Residency | 1 | 2018 | 747 | 0.350 |
Why?
|
| Aged | 8 | 2024 | 13408 | 0.340 |
Why?
|
| Shigella Vaccines | 3 | 2005 | 3 | 0.340 |
Why?
|
| Treatment Outcome | 6 | 2024 | 5283 | 0.290 |
Why?
|
| Cross Infection | 2 | 2020 | 149 | 0.290 |
Why?
|
| Methicillin Resistance | 1 | 2007 | 21 | 0.290 |
Why?
|
| Male | 14 | 2024 | 27749 | 0.280 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 2 | 2020 | 53 | 0.280 |
Why?
|
| Female | 15 | 2024 | 30726 | 0.280 |
Why?
|
| Sepsis | 2 | 2021 | 274 | 0.270 |
Why?
|
| Community-Acquired Infections | 1 | 2007 | 92 | 0.270 |
Why?
|
| Microbial Sensitivity Tests | 3 | 2021 | 191 | 0.270 |
Why?
|
| Middle Aged | 10 | 2024 | 16314 | 0.250 |
Why?
|
| Aged, 80 and over | 5 | 2024 | 5119 | 0.240 |
Why?
|
| Drug Resistance, Bacterial | 3 | 2021 | 83 | 0.230 |
Why?
|
| Shigella flexneri | 1 | 2004 | 19 | 0.220 |
Why?
|
| Demography | 1 | 2024 | 169 | 0.220 |
Why?
|
| Adult | 13 | 2024 | 15681 | 0.220 |
Why?
|
| Enterotoxins | 1 | 2003 | 20 | 0.210 |
Why?
|
| Escherichia coli Vaccines | 1 | 2003 | 11 | 0.210 |
Why?
|
| Hospital Mortality | 2 | 2024 | 842 | 0.200 |
Why?
|
| Bacterial Toxins | 1 | 2003 | 60 | 0.200 |
Why?
|
| Antigens, Bacterial | 1 | 2003 | 200 | 0.190 |
Why?
|
| Multilocus Sequence Typing | 1 | 2021 | 4 | 0.180 |
Why?
|
| Comorbidity | 1 | 2024 | 1078 | 0.180 |
Why?
|
| Enterobacter | 1 | 2020 | 5 | 0.180 |
Why?
|
| Sinorhizobium meliloti | 1 | 2020 | 4 | 0.180 |
Why?
|
| Bacteriuria | 1 | 2020 | 11 | 0.180 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2020 | 24 | 0.170 |
Why?
|
| Plant Roots | 1 | 2020 | 62 | 0.170 |
Why?
|
| Plasmids | 1 | 2021 | 279 | 0.170 |
Why?
|
| Escherichia coli Proteins | 1 | 2003 | 264 | 0.170 |
Why?
|
| Bacterial Proteins | 3 | 2021 | 737 | 0.170 |
Why?
|
| Case-Control Studies | 2 | 2020 | 1051 | 0.160 |
Why?
|
| Shock, Septic | 1 | 2020 | 86 | 0.160 |
Why?
|
| Anti-Infective Agents | 1 | 2021 | 143 | 0.160 |
Why?
|
| Bacterial Infections | 1 | 2020 | 140 | 0.160 |
Why?
|
| Emergency Medical Services | 1 | 2021 | 255 | 0.150 |
Why?
|
| Virulence | 2 | 2017 | 188 | 0.150 |
Why?
|
| Immunocompromised Host | 1 | 2018 | 100 | 0.150 |
Why?
|
| Patient Discharge | 1 | 2021 | 492 | 0.140 |
Why?
|
| Electronic Health Records | 1 | 2021 | 342 | 0.140 |
Why?
|
| Pilot Projects | 1 | 2021 | 914 | 0.140 |
Why?
|
| Bacterial Shedding | 1 | 2017 | 1 | 0.140 |
Why?
|
| Schools, Medical | 1 | 2018 | 141 | 0.140 |
Why?
|
| beta-Lactam Resistance | 1 | 2016 | 4 | 0.130 |
Why?
|
| Virulence Factors | 1 | 2017 | 80 | 0.130 |
Why?
|
| Acinetobacter baumannii | 1 | 2016 | 4 | 0.130 |
Why?
|
| Acinetobacter Infections | 1 | 2016 | 5 | 0.130 |
Why?
|
| Environment | 1 | 2017 | 119 | 0.130 |
Why?
|
| Cattle | 1 | 2017 | 304 | 0.130 |
Why?
|
| Heart Septal Defects, Ventricular | 1 | 2016 | 7 | 0.130 |
Why?
|
| Family Practice | 1 | 2018 | 208 | 0.130 |
Why?
|
| Hyperbaric Oxygenation | 1 | 2016 | 16 | 0.130 |
Why?
|
| Endocarditis, Bacterial | 1 | 2016 | 31 | 0.130 |
Why?
|
| Host-Pathogen Interactions | 1 | 2017 | 240 | 0.120 |
Why?
|
| Shigella sonnei | 2 | 2005 | 3 | 0.110 |
Why?
|
| Antibodies, Bacterial | 3 | 2004 | 187 | 0.110 |
Why?
|
| Pulmonary Embolism | 1 | 2016 | 169 | 0.110 |
Why?
|
| Hospitals | 3 | 2021 | 378 | 0.110 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2018 | 692 | 0.100 |
Why?
|
| Mutation | 1 | 2021 | 2456 | 0.100 |
Why?
|
| Surveys and Questionnaires | 1 | 2018 | 2516 | 0.090 |
Why?
|
| Vaccines, Attenuated | 3 | 2005 | 33 | 0.080 |
Why?
|
| Endocarditis | 1 | 2009 | 19 | 0.080 |
Why?
|
| Child | 1 | 2018 | 4189 | 0.080 |
Why?
|
| Immunoglobulin A | 3 | 2005 | 94 | 0.080 |
Why?
|
| Administration, Oral | 3 | 2005 | 355 | 0.070 |
Why?
|
| Staphylococcal Skin Infections | 1 | 2007 | 13 | 0.070 |
Why?
|
| Treatment Failure | 1 | 2007 | 185 | 0.070 |
Why?
|
| Cohort Studies | 3 | 2020 | 2375 | 0.070 |
Why?
|
| Immunoglobulin G | 2 | 2005 | 446 | 0.060 |
Why?
|
| Databases, Factual | 1 | 2007 | 814 | 0.060 |
Why?
|
| Adolescent | 3 | 2004 | 5838 | 0.060 |
Why?
|
| Phenotype | 1 | 2007 | 1137 | 0.050 |
Why?
|
| Feces | 1 | 2004 | 97 | 0.050 |
Why?
|
| Capsules | 1 | 2003 | 34 | 0.050 |
Why?
|
| Vaccines, Synthetic | 1 | 2003 | 68 | 0.050 |
Why?
|
| Immunization | 1 | 2003 | 128 | 0.050 |
Why?
|
| Immunity, Cellular | 1 | 2003 | 171 | 0.050 |
Why?
|
| Disease Outbreaks | 1 | 2021 | 102 | 0.050 |
Why?
|
| Ascitic Fluid | 1 | 2020 | 12 | 0.040 |
Why?
|
| Risk Factors | 2 | 2020 | 4986 | 0.040 |
Why?
|
| Urinalysis | 1 | 2020 | 30 | 0.040 |
Why?
|
| Ventriculoperitoneal Shunt | 1 | 2020 | 30 | 0.040 |
Why?
|
| Patient Readmission | 1 | 2024 | 421 | 0.040 |
Why?
|
| Causality | 1 | 2020 | 57 | 0.040 |
Why?
|
| ROC Curve | 1 | 2021 | 267 | 0.040 |
Why?
|
| Early Diagnosis | 1 | 2020 | 91 | 0.040 |
Why?
|
| Hydrocephalus | 1 | 2020 | 43 | 0.040 |
Why?
|
| Device Removal | 1 | 2020 | 64 | 0.040 |
Why?
|
| Time-to-Treatment | 1 | 2020 | 98 | 0.040 |
Why?
|
| Continuity of Patient Care | 1 | 2020 | 170 | 0.040 |
Why?
|
| Animals | 1 | 2017 | 19650 | 0.040 |
Why?
|
| Environmental Exposure | 1 | 2020 | 208 | 0.040 |
Why?
|
| DNA-Binding Proteins | 1 | 2004 | 1151 | 0.040 |
Why?
|
| Intensive Care Units | 1 | 2020 | 423 | 0.030 |
Why?
|
| Incidence | 1 | 2020 | 1238 | 0.030 |
Why?
|
| Cefazolin | 1 | 2016 | 9 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2004 | 1471 | 0.030 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2016 | 78 | 0.030 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2016 | 92 | 0.030 |
Why?
|
| Inappropriate Prescribing | 1 | 2016 | 64 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 396 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2016 | 902 | 0.030 |
Why?
|
| Pregnancy | 1 | 2020 | 2213 | 0.030 |
Why?
|
| Lipopolysaccharides | 2 | 2005 | 627 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2009 | 163 | 0.020 |
Why?
|
| Outpatients | 1 | 2009 | 137 | 0.020 |
Why?
|
| United States | 1 | 2020 | 7426 | 0.020 |
Why?
|
| Antibody-Producing Cells | 1 | 2005 | 12 | 0.020 |
Why?
|
| Dysentery, Bacillary | 1 | 2005 | 14 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2005 | 293 | 0.010 |
Why?
|
| Lactoferrin | 1 | 2002 | 36 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2002 | 715 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 2002 | 551 | 0.010 |
Why?
|
| Young Adult | 1 | 2009 | 4272 | 0.010 |
Why?
|